Business
Macquarie trims CSL’s price target and outlook – The Australian Financial Review
As new COVID-19 cases surge in the US unemployment benefits and travel restrictions on Mexican citizens are limiting plasma collection….
Macquarie analysts estimated that foot traffic for about 100 of CSLs US-based plasma collection centres has remained subdued following a step-down in June, leading the investment bank to reduce its fiscal 2022 immunoglobulin volume growth assumptions.
Macquarie…
Continue Reading
